NasdaqGS:NVAXBiotechs
Why Novavax (NVAX) Is Up 10.2% After Partnership-Fueled Return To Full-Year Profitability – And What's Next
In late February 2026, Novavax reported Q4 2025 revenue of US$147.14 million and net income of US$17.53 million, marking a move from loss-making to profitable operations for both the quarter and full year.
This earnings swing was heavily supported by partnership-driven milestone payments and improved cost efficiency, underscoring how its collaboration-led model is now a central driver of profitability.
Next, we’ll examine how this partnership-fueled return to profitability reshapes...